Outset Medical Reports First Quarter 2024 Financial Results

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Insights

Outset Medical's Q1 2024 report shows a revenue decline from $33.5 million to $28.2 million year-over-year, despite a substantial growth in service revenue and recurring sales from Tablo cartridges. This juxtaposition signals the company's increasing reliance on its service model and consumables, offsetting the dip in product revenue. The reported 12th consecutive quarter of gross margin expansion, reaching 29.2%, is particularly noteworthy, demonstrating improved operational efficiency, which is important for investors looking at long-term sustainability. However, the net loss has reduced from $(44.0) million to $(39.9) million, which still reflects significant losses per share, but an improvement over the previous year. It's commendable that operating expenses saw a 10% reduction, indicating effective cost management strategies. With $230.2 million in total cash, liquidity doesn't seem to be an immediate concern and with no additional capital needed, the company appears stable in its path to achieving cash-flow breakeven. The reaffirmed 2024 guidance suggests confidence in the company's strategy, but it's essential to monitor if they meet the projected revenue growth of 12% to 18%. For a retail investor, these figures suggest Outset is on a trajectory of operational improvement, though still navigating through losses.

Outset Medical operates within the $11 billion U.S. dialysis market, carving a niche with their Tablo system. The recent 510(k) clearance for TabloCart with Prefiltration enhances their competitive edge, potentially increasing product adoption and market share. Customer wins in both acute- and home-care settings suggest strong market acceptance and may predict future revenue growth. However, the 24% recurring revenue increase from Tablo cartridges indicates not just a one-time purchase but an ongoing demand for their consumables, which is a positive indicator for the sustainability of the revenue stream. Considering the heightened interest in home dialysis spurred by the pandemic and policy shifts, Outset's positioning could cater well to these trends. The increase of service revenues by 36.1% year-over-year, though significantly contributing to the bottom line, hints at a strategic transition to more reliable, recurring income streams. Overall, the company’s financial health and strategic direction look promising, but investors should weigh the current losses against the potential market growth and the company's strategic initiatives.

Assessing Outset's first-quarter results from a risk perspective, several factors stand out. The 14.8% YoY revenue drop may raise eyebrows, but this must be balanced against the impressive gross margin increase of nearly 10 percentage points. This indicates that Outset is not just maintaining but improving its profitability per unit, a green flag for potential investors. The service revenue increase is significant, pointing to a robust and growing customer base, reducing the risk associated with reliance on one-time sales. However, the consistent net losses necessitate caution. They imply that despite operational tightening, the path to profitability is ongoing and not without its obstacles. Despite this, the company's strong cash reserves provide a buffer against short-term market fluctuations and offer the financial flexibility to continue operations without seeking additional capital. For investors, the trade-off here is between the company's clear strides in market penetration and operational efficiency and the equally clear need to pivot toward net profitability.

05/08/2024 - 04:02 PM

SAN JOSE, Calif.--(BUSINESS WIRE)-- Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2024.

“With our recent 510(k) clearance for TabloCart with Prefiltration, 12^th consecutive quarter of gross margin expansion and strong sales pipeline growth during the quarter, we are well positioned to capitalize on the $11 billion U.S. dialysis market opportunity,” said Leslie Trigg, Chair and Chief Executive Officer. “Tablo’s uniquely compelling value proposition continues to resonate with acute- and home-care providers, with significant new customer wins in both settings during the quarter.

“We also took cost-reduction steps during the quarter to help ensure we reach our profitability goals without the need for additional capital. We believe these actions, combined with continued gross margin expansion and a strong recurring revenue foundation, now provide us a clear path to achieve cash-flow breakeven sooner than previously expected.”

First Quarter 2024 Financial Results

Revenue for the first quarter of 2024 was $28.2 million compared to $33.5 million in the first quarter of 2023, driven by an expected decline in product revenue to $20.4 million. Service and other revenue was $7.7 million, an increase of 36.1% compared to $5.7 million in the first quarter of 2023. Recurring revenue from the sale of Tablo cartridges and service increased by 24% as compared to the prior-year period.

Total gross profit was $8.2 million, compared to $6.4 million for the first quarter of 2023. Total gross margin was 29.2%, compared to 19.2% in the first quarter of 2023. On a non-GAAP basis, gross margin improved to 31.1% from 20.3% in the first quarter of 2023. Product gross profit was $7.8 million, compared to $7.0 million of product gross profit in the first quarter of 2023. Product gross margin was 38.4%, compared to 25.1% in the first quarter of 2023. Service and other gross profit was $0.4 million, compared to $(0.5) million of service and other gross profit in the first quarter of 2023. Service and other gross margin was 4.8%, compared to (9.4)% in the first quarter of 2023.

Operating expenses declined 10% from the prior-year period to $45.1 million, including research and development (R&D) expenses of $12.6 million, sales and marketing (S&M) expenses of $21.0 million, and general and administrative (G&A) expenses of $11.4 million. This compared to operating expenses of $49.9 million in the first quarter of 2023, including R&D expenses of $13.8 million, S&M expenses of $24.3 million, and G&A expenses of $11.8 million.

Excluding stock-based compensation expense and severance and related charges, net of adjustments to compensation accrual, non-GAAP operating expenses were $35.0 million, including R&D expenses of $9.3 million, S&M expenses of $18.8 million, and G&A expenses of $6.9 million.

Net loss was $(39.9) million, or $(0.78) per share, compared to net loss of $(44.0) million, or $(0.90) per share, for the same period in 2023. On a non-GAAP basis, net loss was $(29.3) million, or $(0.57) per share, compared to non-GAAP net loss of $(35.4) million, or $(0.72) per share for the same period in 2023.

Total cash, including restricted cash, cash equivalents and short-term investments, was $230.2 million as of March 31, 2024.

Full Year 2024 Financial Guidance

Outset reaffirmed its previously provided guidance for 2024 including revenue of $145 million to $153 million, growing 12% to 18% over 2023, and non-GAAP gross margin in the low-30% range for the full year 2024, exiting the year in the mid-30% range for the fourth quarter.

Webcast and Conference Call Details

Outset will host a conference call today, May 8, 2024, at 2:00 p.m. PT / 5:00 p.m. ET to discuss its first quarter 2024 financial results. Those interested in listening to the conference call may do so by registering online. Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.outsetmedical.com. The webcast will be archived on the website following the completion of the call.

Use of Non-GAAP Financial Measures

The Company may report non-GAAP results for gross profit/loss, gross margin, operating expenses, operating margins, net income/loss, basic and diluted net income/loss per share, other income/loss, and cash flows. These non-GAAP financial measures are in addition to, and not a substitute for, or superior to, financial measures calculated in accordance with GAAP. As listed in the itemized reconciliations between GAAP and non-GAAP financial measures included in this press release, the Company’s GAAP financial measures include stock-based compensation expense, as well as severance and related charges net of the reversal of compensation accruals for impacted employees. Stock-based compensation is a non-cash expense, and severance and related charges arise outside the ordinary course of continuing operations and are not reflective of the Company’s current operating performance. As such, management has excluded the effects of these items in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance and period-to-period comparisons. There are limitations related to the use of non-GAAP financial measures because they are not prepared in accordance with GAAP, may exclude significant expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the Appendix A of this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the Company’s possible or assumed future results of operations and financial position, including expectations regarding projected revenues, gross margin, operating expenses, capital expenditures, cash burn, cash position, profitability and outlook; statements about the Company’s ability to meet its profitability goals without the need for additional capital and expectations on the timing of achieving cash-flow breakeven; statements regarding the anticipated impacts and benefits of the Company’s cost reduction actions; statements regarding the Company’s overall business strategy, plans and objectives of management; the Company’s expectations regarding the market sizes and growth potential for Tablo and the total addressable market opportunities for Tablo; continued execution of the Company’s initiatives designed to expand gross margins; the Company’s ability to respond to and resolve any reports, observations or other actions by the Food and Drug Administration or other regulators in a timely and effective manner; as well as the Company’s expectations regarding the impact of macroeconomic factors on the Company, its customers and suppliers. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission, including its latest annual and quarterly reports. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

Outset Medical, Inc. Condensed Statements of Operations (in thousands, except per share amounts) (unaudited)

	Three Months Ended
	March 31,
	2024			2023
Revenue:
Product revenue	$	20,428		$	27,779
Service and other revenue		7,740			5,688
Total revenue		28,168			33,467
Cost of revenue:
Cost of product revenue⁽²⁾		12,581			20,817
Cost of service and other revenue		7,372			6,222
Total cost of revenue		19,953			27,039
Gross profit ⁽¹⁾		8,215			6,428
Gross margin ⁽¹⁾		29.2	%		19.2	%
Operating expenses:
Research and development ⁽²⁾		12,635			13,793
Sales and marketing ⁽²⁾		21,048			24,333
General and administrative⁽²⁾		11,444			11,787
Total operating expenses		45,127			49,913
Loss from operations		(36,912	)		(43,485	)
Interest income and other income, net		3,098			2,648
Interest expense		(5,968	)		(2,942	)
Loss before provision for income taxes		(39,782	)		(43,779	)
Provision for income taxes		162			192
Net loss	$	(39,944	)	$	(43,971	)

Net loss per share, basic and diluted	$	(0.78	)	$	(0.90	)
Shares used in computing net loss per share, basic and diluted		50,901			48,783


⁽¹⁾ Gross profit and gross margin by source consisted of the following:

	Three Months Ended
	March 31,
	2024			2023
Gross profit
Product revenue	$	7,847		$	6,962
Service and other revenue		368			(534	)
Total gross profit	$	8,215		$	6,428
Gross margin
Product revenue		38.4	%		25.1	%
Service and other revenue		4.8	%		(9.4	)%
Total gross margin		29.2	%		19.2	%

⁽²⁾ Include stock-based compensation expense and severance and related charges, net as follows:

	Three Months Ended
Stock-based compensation expense	March 31,
	2024			2023
Cost of revenue	$	265		$	358
Research and development		2,332			2,615
Sales and marketing		1,459			2,598
General and administrative		4,147			2,967
Total stock-based compensation expense	$	8,203		$	8,538

	Three Months Ended
Severance and related charges, net*	March 31,
	2024			2023
Cost of revenue	$	279		$	—
Research and development		990			—
Sales and marketing		793			—
General and administrative		411			—
Total severance and related charges, net	$	2,473		$	—
* Net of adjustments to compensation accrual

Outset Medical, Inc. Condensed Balance Sheets (in thousands, except per share amounts)

	March 31,			December 31,
	2024			2023
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	32,176		$	68,509
Short-term investments		194,743			134,815
Accounts receivable, net		36,478			32,980
Inventories		55,839			49,215
Prepaid expenses and other current assets		6,155			5,700
Total current assets		325,391			291,219
Restricted cash		3,329			3,329
Property and equipment, net		11,953			13,273
Operating lease right-of-use assets		5,029			5,375
Other assets		540			605
Total assets	$	346,242		$	313,801
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	6,773		$	5,827
Accrued compensation and related benefits		14,248			19,005
Accrued expenses and other current liabilities		11,968			13,459
Accrued warranty liability		3,200			3,712
Deferred revenue, current		12,839			11,727
Operating lease liabilities, current		1,642			1,593
Total current liabilities		50,670			55,323
Accrued interest		1,319			896
Deferred revenue		186			101
Operating lease liabilities		4,054			4,482
Term loans		196,813			130,113
Total liabilities		253,042			190,915
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of March 31, 2024 and December 31, 2023		—			—
Common stock, $0.001 par value; 300,000 shares authorized as of March 31, 2024 and December 31, 2023; 51,702 and 50,317 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively		52			50
Additional paid-in capital		1,095,097			1,084,515
Accumulated other comprehensive income (loss)		(258	)		68
Accumulated deficit		(1,001,691	)		(961,747	)
Total stockholders' equity		93,200			122,886
Total liabilities and stockholders' equity	$	346,242		$	313,801

Outset Medical, Inc. Condensed Statements of Cash Flows (in thousands) (unaudited)

	Three Months Ended March 31,
	2024			2023
Net cash used in operating activities	$	(45,912	)	$	(44,756	)
Net cash (used in) provided by investing activities		(59,031	)		2,643
Net cash provided by financing activities		68,610			5,277
Net decrease in cash, cash equivalents and restricted cash		(36,333	)		(36,836	)
Cash, cash equivalents and restricted cash at beginning of the period		71,838			76,533
Cash, cash equivalents and restricted cash at end of the period ⁽¹⁾	$	35,505		$	39,697


⁽¹⁾ The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed balance sheets that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands):

	March 31,
	2024			2023
Cash and cash equivalents	$	32,176		$	36,386
Restricted cash		3,329			3,311
Total cash, cash equivalents and restricted cash^*	$	35,505		$	39,697

* The total cash, including restricted cash, cash equivalents and investment securities as of March 31, 2024 was $230.2 million; compared to $252.5 million as of March 31, 2023.

Appendix A
Outset Medical, Inc. Results of Operations – Non-GAAP (in thousands, except per share amounts) (unaudited)

Reconciliation between GAAP and non-GAAP net loss per share:

	Three Months Ended
	March 31,
	2024			2023
GAAP net loss per share, diluted	$	(0.78	)	$	(0.90	)
Stock-based compensation expense		0.16			0.18
Severance and related charges, net		0.05			—
Non-GAAP net loss per share, diluted	$	(0.57	)	$	(0.72	)

Reconciliation between GAAP and non-GAAP net loss:

	Three Months Ended
	March 31,
	2024			2023
GAAP net loss, diluted	$	(39,944	)	$	(43,971	)
Stock-based compensation expense		8,203			8,538
Severance and related charges, net		2,473			—
Non-GAAP net loss, diluted	$	(29,268	)	$	(35,433	)

Reconciliation between GAAP and non-GAAP results of operations:

	Three Months Ended
	March 31,
	2024			2023
GAAP gross profit	$	8,215		$	6,428
Stock-based compensation expense		265			358
Severance and related charges, net		279			—
Non-GAAP gross profit	$	8,759		$	6,786

GAAP gross margin		29.2	%		19.2	%
Stock-based compensation expense		0.9			1.1
Severance and related charges, net		1.0			—
Non-GAAP gross margin		31.1	%		20.3	%

GAAP research and development expense	$	12,635		$	13,793
Stock-based compensation expense		(2,332	)		(2,615	)
Severance and related charges, net		(990	)		—
Non-GAAP research and development expense	$	9,313		$	11,178

GAAP sales and marketing expense	$	21,048		$	24,333
Stock-based compensation expense		(1,459	)		(2,598	)
Severance and related charges, net		(793	)		—
Non-GAAP sales and marketing expense	$	18,796		$	21,735

GAAP general and administrative expense	$	11,444		$	11,787
Stock-based compensation expense		(4,147	)		(2,967	)
Severance and related charges, net		(411	)		—
Non-GAAP general and administrative expense	$	6,886		$	8,820

GAAP total operating expense	$	45,127		$	49,913
Stock-based compensation expense		(7,938	)		(8,180	)
Severance and related charges, net		(2,194	)		—
Non-GAAP total operating expense	$	34,995		$	41,733

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508960019/en/

Investor Contact

Jim Mazzola

Investor Relations

jmazzola@outsetmedical.com

Source: Outset Medical, Inc.

FAQ

What was Outset Medical's revenue for the first quarter of 2024?

Outset Medical reported revenue of $28.2 million for the first quarter of 2024.

What was the total gross margin for Outset Medical in the first quarter of 2024?

Outset Medical's total gross margin was 29.2% in the first quarter of 2024, compared to 19.2% in the first quarter of 2023.

What was the net loss for Outset Medical in the first quarter of 2024?

Outset Medical had a net loss of $(39.9) million, or $(0.78) per share, in the first quarter of 2024.

What is Outset Medical's full year 2024 revenue guidance?

Outset reaffirmed its guidance for 2024 with revenue expected to be in the range of $145 million to $153 million, growing 12% to 18% over 2023.

Where can I listen to Outset Medical's first quarter 2024 financial results conference call?

You can listen to Outset Medical's conference call discussing its first quarter 2024 financial results by registering online on the Investor Relations section of the company's website.

Outset Medical Reports First Quarter 2024 Financial Results

Insights

FAQ

What was Outset Medical's revenue for the first quarter of 2024?

What was the total gross margin for Outset Medical in the first quarter of 2024?

What was the net loss for Outset Medical in the first quarter of 2024?

What is Outset Medical's full year 2024 revenue guidance?

Where can I listen to Outset Medical's first quarter 2024 financial results conference call?

NASDAQ:OM

OM Rankings

OM Latest News

OM Stock Data

Trending News

Outset Medical Reports First Quarter 2024 Financial Results

Insights

Financial Analyst neutral

Medical Technology Market Analyst neutral

Investment Risk Analyst neutral

FAQ

What was Outset Medical's revenue for the first quarter of 2024?

What was the total gross margin for Outset Medical in the first quarter of 2024?

What was the net loss for Outset Medical in the first quarter of 2024?

What is Outset Medical's full year 2024 revenue guidance?

Where can I listen to Outset Medical's first quarter 2024 financial results conference call?

NASDAQ:OM

OM Rankings

OM Latest News

OM Stock Data